the Paperwork Reduction Act of 1995, no persons are required to re

PTO/SB/82 (09-03)

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY CHANGE OF CORRESPONDENCE ADDRESS

98	spond to a collection of information unless it displays a valid OMB control number				
	Application Number	09/933,106			
	Filing Date	08/20/2001			
	First Named Inventor	Wai Wong			
	Art Unit	1624			
	Examiner Name	V. Balasubramanian			
	Attorney Docket Number	45990-ZAA			

I hereby revoke all previous powers of attorney given in the above-identified application.								
A Power of Attorney is submitted herewith.								
OR I hereby appoint the practitioners associated with the Customer Number: 45821								
Please change the correspondence address for the above-identified application to:								
The address associated with Customer Number: 45821								
OR			<u>-</u>					
Firm or Individual Name								
Address								
Address								
City		S	state		Zip			
Country		· · · · · · · · · · · · · · · · · · ·						
Telephone			Fax					
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71.								
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)								
Name JOHN MEIDAHI DIVISIONAL DIRECTOR CORPORATE PATENTS & TRADEMARKS HILLINDRECK A/S								
OF THE TRANSPORT OF THE								
Signature de de de la Tolophone 1500 1000 1								
Date //0/22/2004 Telephone +4536433204								
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.								
*Total offorms are submitted.								

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/96 (06-04) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)							
Applicant/Patent Owner: H. LUNDBECK, A/S							
Application No./Patent No.: 6,777,426	iled/Issue Date:	08/17/2004					
Entitled: IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF							
H. LUNDBECK, A/S, a	A CORPORATION	OF DENMARK					
(Name of Assignee)	(Type of Assignee, e.g., co	prporation, partnership, university, government agency, etc.)					
states that it is: 1. ☑ the assignee of the entire right, title, and interest;	or						
2. an assignee of less than the entire right, title and The extent (by percentage) of its ownership interesting the patent application/patent identified above by virtue.	est is%						
A. [] An assignment from the inventor(s) of the patent in the United States Patent and Trademark Office attached.							
OR							
B. 区 A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:							
1. From: Wai Wong, et al	TO: SYNAPTIC P	HARMACEUTICAL CORPORATION					
The document was recorded in the United States Patent and Trademark Office at Reel 8805, Frame 0149, or for which a copy thereof is attached.							
2. From: SYNAPTIC PHARMACEUTICAL CORPORATI	ON To: H. LUNDBEC	CK, A/S					
The document was recorded in the United States Patent and Trademark Office at Reel 015156, Frame 0196, or for which a copy thereof is attached.							
3. From:							
The document was recorded in the United Reel, Frame							
[] Additional documents in the chain of title a	re listed on a supplem	ental sheet.					
[] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (<i>i.e.</i> , a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]							
The undersigned (whose title is supplied below) is authorized by the supplied below is authorized.	orized to act on behalf	of the assignee. 10/22/04					
Signature		Date					
JOHN MEIDAHL		+4536433204					
Printed or Typed Name		Telephone Number					
DIVISIONAL DIRECTOR CORPORATE PATENTS & TRAD	DEMARKS, H. LUNDBECK	A/S					
Title							

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.